Legend Biotech Corporation (FRA:9LB)

Market Cap	4.41B
Revenue (ttm)	774.78M
Net Income (ttm)	-204.30M
Shares Out	n/a
EPS (ttm)	-1.11
PE Ratio	n/a
Forward PE	125.39
Dividend	n/a
Ex-Dividend Date	n/a

Volume	200
Average Volume	72
Open	24.20
Previous Close	24.00
Day's Range	23.60 - 24.20
52-Week Range	23.00 - 42.00
Beta	n/a
RSI	35.17
Earnings Date	Mar 11, 2026

About Legend Biotech

Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgk...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2014
• Employees: 2,600
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 9LB

Financial Performance

In 2024, Legend Biotech's revenue was $627.24 million, an increase of 119.97% compared to the previous year's $285.14 million. Losses were -$177.03 million, -65.84% less than in 2023.

Financial numbers in USD